Background: Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive tumour. Adequate margins have a positive impact on recurrence rates. The aim of this study is to assess how adequate margins are achieved and secondly which additional treatment modalities might be necessary to achieve adequate margins. Material & methods: Patients with DFSP treated between 1991 and 2016 at three tertiary centres were included. Patient- and tumour characteristics were obtained from a prospectively held database and patient files. Results: A total of 279 patients with a median age of 39 (Interquartile range [IQ], 31–50) years and a median follow-up of 50 (IQ, 18–96) months were included. When DFSP was preoperatively confirmed by biopsy and resected with an oncological operation in a tertiary centre, in 86% was had clear pathological margins after one excision. Wider resection margins were significantly correlated with more reconstructions (p = 0.002). A substantial discrepancy between the primary surgical macroscopic and the pathological margins was found with a median difference of 22 (range, 10–46) mm (Fig. 1). There was no significant influence of the width of the pathological clear margins (if > 1 mm) and the recurrence rate (p = 0.710). Conclusion: The wider the resection margins, the more likely it is to obtain clear pathological margins, but the more likely patients will need any form of reconstruction after resection. The aim of the primary excision should be wide surgical resection, where the width of the margin should be balanced against the need for reconstructions and surgical morbidity.

Additional Metadata
Keywords Dermatofibrosarcoma protuberans, DFSP, Resection margins, Surgical treatment
Persistent URL,
Journal European Journal of Surgical Oncology
Huis in ’t Veld, E.A. (E. A.), Grunhagen, D.J, van Coevorden, F, Smith, M.J. (M. J.), van Akkooi, A.C.J, Wouters, M.W.J.M, … van Houdt, W.J. (2020). Adequate surgical margins for dermatofibrosarcoma protuberans – A multi-centre analysis. European Journal of Surgical Oncology. doi:10.1016/j.ejso.2020.06.022